We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$22.8B
AUM Growth
+$1.74M
Cap. Flow
+$81.8M
Cap. Flow %
0.36%
Top 10 Hldgs %
82.65%
Holding
132
New
12
Increased
20
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$137M
2
PACB icon
Pacific Biosciences
PACB
+$66.5M
3
KOD icon
Kodiak Sciences
KOD
+$50.2M
4
BLUE
bluebird bio
BLUE
+$50.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$34M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$144M
2
ADCT icon
ADC Therapeutics
ADCT
+$34.5M
3
AMRN
Amarin Corp
AMRN
+$22.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$20.4M
5
NVTA
Invitae Corporation
NVTA
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
76
Edgewise Therapeutics
EWTX
$4.8B
$8.3M 0.04%
500,000
– –
CABA icon
77
Cabaletta Bio
CABA
$531M
$8.05M 0.04%
662,063
+25,700
+4% +$237K
CBAY
78
DELISTED
Cymabay Therapeutics
CBAY
$7.92M 0.03%
2,170,464
– –
LONA
79
LeonaBio Inc
LONA
$72.4M
$7.56M 0.03%
80,637
– –
GTH
80
DELISTED
Genetron Holdings Limited ADS
GTH
$6.31M 0.03%
151,769
– –
BMEA icon
81
Biomea Fusion
BMEA
$99.3M
$6.28M 0.03%
524,617
+230,500
+78% +$2.93M
AMYT
82
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$6.24M 0.03%
+518,380
New +$5.85M
NGM
83
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$6.13M 0.03%
291,801
– –
RVMD icon
84
Revolution Medicines
RVMD
$44.9B
$6.11M 0.03%
222,222
– –
KURA icon
85
Kura Oncology
KURA
$1.06B
$5.7M 0.03%
+304,158
New +$5.73M
ATYR
86
aTyr Pharma
ATYR
$49.2M
$5.67M 0.02%
+625,000
New +$3.74M
ALEC icon
87
Alector
ALEC
$264M
$5.46M 0.02%
239,228
– –
RLMD icon
88
Relmada Therapeutics
RLMD
$494M
$5.27M 0.02%
200,996
+124,396
+162% +$3.33M
CCXI
89
DELISTED
ChemoCentryx, Inc.
CCXI
$5.15M 0.02%
+301,195
New +$4.69M
TCDA
90
DELISTED
Tricida, Inc. Common Stock
TCDA
$4.81M 0.02%
1,037,432
+308,132
+42% +$1.28M
HRMY icon
91
Harmony Biosciences
HRMY
$2.22B
$4.74M 0.02%
123,600
– –
REPL icon
92
Replimune Group
REPL
$1.39B
$4.55M 0.02%
153,512
– –
DNLI icon
93
Denali Therapeutics
DNLI
$3.98B
$4.48M 0.02%
88,738
– –
NEXI
94
DELISTED
NexImmune, Inc. Common Stock
NEXI
$4.45M 0.02%
11,765
– –
HOOK
95
DELISTED
HOOKIPA Pharma
HOOK
$4.13M 0.02%
70,048
– –
ITOS
96
DELISTED
iTeos Therapeutics
ITOS
$4.06M 0.02%
150,346
– –
VINC
97
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$3.9M 0.02%
+12,069
New +$3.52M
XLRN
98
DELISTED
Acceleron Pharma
XLRN
$3.86M 0.02%
22,430
– –
BNR
99
Burning Rock Biotech
BNR
$103M
$3.74M 0.02%
20,913
– –
AKRO
100
DELISTED
Akero Therapeutics
AKRO
$2.65M 0.01%
118,378
– –
2 3
4
5 6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2021 Portfolio in Review

As of Q3 2021, Julian Baker held 132 positions worth $22.8B, up 0.01% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker's Q3 2021 filing shows 12 new, 20 increased, 6 reduced and 10 closed positions. Its largest new stake was Surrozen: 166,667 shares worth $17.7M. The largest sale was Apellis Pharmaceuticals, an estimated $144M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q3 2021 buy was Surrozen: 166,667 shares worth $17.7M.
  • Julian Baker added most to Ascendis Pharma A/S in Q3 2021, an estimated $137M increase.
  • Julian Baker's biggest Q3 2021 reduction was Amarin Corp, cutting an estimated $22.6M.
  • Julian Baker fully exited Apellis Pharmaceuticals in Q3 2021, selling an estimated $144M.
  • Julian Baker's ten largest holdings make up 83% of its $22.8B portfolio in Q3 2021.
  • Julian Baker opened 12 new positions and closed 10 in Q3 2021.
  • Julian Baker's portfolio value rose 0.01% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.